Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 13;33(10):1201–1214. doi: 10.1089/thy.2023.0201

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2023, Mary Ann Liebert, Inc., publishers

PMC Copyright notice

FIG. 2. — The combination of BRAF inhibition and axitinib treatment inhibits cell migration and invasion in BRAF^V600E-mutant ATC cells. (A) The combination of PLX4720 (15 μM) and axitinib (1.89 μM) significantly inhibited cell migration compared with vehicle (p < 0.0001), PLX4720 (p < 0.01 and p < 0.05), and axitinib (p < 0.0001) in both cell lines. The combination of dabrafenib and axitinib significantly reduced cell migration compared with vehicle (p < 0.0001) and axitinib (p < 0.0001) in both cell lines 24 hours after scratching. (B) The histogram represents the mean wound area remaining 24 hours after scratching 8505C and SW1736 cells. The data are shown as the mean ± SD. (C) PLX4720 and axitinib treatment significantly reduced cell invasion after 24 hours compared with vehicle (p < 0.0001 and p < 0.001), PLX4720 (p < 0.001), and axitinib (p < 0.001) in 8505C and SW1736 cells. The combination of dabrafenib and axitinib inhibited cell invasion significantly more compared with vehicle (p < 0.0001 and p < 0.001) in both cell lines. (D) The histogram represents the mean number of cells that invaded the membrane/field of image. The data are shown as the mean ± SD. For all panels, the black stars denote combination versus vehicle, the blue stars denote combination versus BRAF inhibitor (PLX4720 and dabrafenib), and the red stars denote combination versus axitinib.

FIG. 2. — The combination of BRAF inhibition and axitinib treatment inhibits cell migration and invasion in BRAF^V600E-mutant ATC cells. (A) The combination of PLX4720 (15 μM) and axitinib (1.89 μM) significantly inhibited cell migration compared with vehicle (p < 0.0001), PLX4720 (p < 0.01 and p < 0.05), and axitinib (p < 0.0001) in both cell lines. The combination of dabrafenib and axitinib significantly reduced cell migration compared with vehicle (p < 0.0001) and axitinib (p < 0.0001) in both cell lines 24 hours after scratching. (B) The histogram represents the mean wound area remaining 24 hours after scratching 8505C and SW1736 cells. The data are shown as the mean ± SD. (C) PLX4720 and axitinib treatment significantly reduced cell invasion after 24 hours compared with vehicle (p < 0.0001 and p < 0.001), PLX4720 (p < 0.001), and axitinib (p < 0.001) in 8505C and SW1736 cells. The combination of dabrafenib and axitinib inhibited cell invasion significantly more compared with vehicle (p < 0.0001 and p < 0.001) in both cell lines. (D) The histogram represents the mean number of cells that invaded the membrane/field of image. The data are shown as the mean ± SD. For all panels, the black stars denote combination versus vehicle, the blue stars denote combination versus BRAF inhibitor (PLX4720 and dabrafenib), and the red stars denote combination versus axitinib.